NGeneBio attended the International Conference of the Korean Society of Clinical Laboratory Science (LMCE 2022), which took place at the Seoul Swiss Grand Hotel Convention Center from October 26 to October 28, 2022.

During this academic conference, we introduced a range of precision diagnostic products, with a particular focus on our Next-Generation Sequencing (NGS) technology-based product, HLAaccuTest™. Additionally, we highlighted our tuberculosis diagnostic product, MTBaccuPanel™, as well as precision diagnostic products for breast cancer and ovarian cancer known as BRCAaccuTest™. We also presented our precision diagnostic test for blood-related cancers, called HEMEaccuTest™.

Through our participation in this conference, NGeneBio solidified its position as a leading company in NGS precision diagnostics, showcasing a variety of precision diagnostic products based on Next-Generation Sequencing. We are committed to continually addressing unmet needs in the medical field and playing a pivotal role in the growth of the diagnostic medical device industry.